Edition:
United Kingdom

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.50USD
3:30pm GMT
Change (% chg)

$0.01 (+1.01%)
Prev Close
$1.48
Open
$1.46
Day's High
$1.54
Day's Low
$1.46
Volume
3,853
Avg. Vol
76,272
52-wk High
$3.34
52-wk Low
$1.11

Summary

Name Age Since Current Position

Roderick Carter

2016 Executive Chairman of the Board

Janelle D'Alvise

2017 President, Chief Executive Officer, Director

Linda O'Keefe

2016 Chief Financial Officer

Pierre Lemieux

2010 Chief Operating Officer

Laurent Harvey

Vice President- Clinical and Non-Clinical Affairs

Jean-Daniel Belanger

Secretary, Director- Corporate Affairs

Jean-Marie Canan

60 2017 Director

Katherine Crewe

2017 Director

Richard Schottenfeld

2017 Director

Biographies

Name Description

Roderick Carter

Dr. Roderick Carter is Executive Chairman of the Board of the company. Carter held various commercial and research leadership roles including Merck and Pfizer. He was vice-president of clinical development at Reliant Pharmaceuticals, which developed the omega-3 cardiovascular drug Lovaza and today is a wholly owned subsidiary of GlaxoSmithKline.

Janelle D'Alvise

Ms. Janelle D'Alvise serves as President, Chief Executive Officer, Director of the Company. She has extensive experience in diagnostics, medical devices, pharmaceuticals and drug discovery research tools. Until recently, Ms. D'Alvise was the President and Chairman of Pediatric Bioscience. Before that, she was the CEO of Gish Biomedical, a cardiopulmonary medical device company. Prior to Gish, Ms. D'Alvise was the CEO of the Sidney Kimmel Cancer Center (SKCC), a drug discovery research institute. From 1995, she was also the Co-Founder and Executive VP/COO of Metrika Inc., and in 1999 was the Co-Founder/President/CEO/ Chairman of NuGEN, Inc. Ms. D'Alvise built both companies from technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth. Prior to 1995, Ms. D'Alvise was a VP of Drug Development at Syntex/Roche and Business Unit Director of their Pain and Inflammation business, and also VP of Commercial Operations at SYVA, (Syntex's clinical diagnostics division), and began her career with Diagnostic Products Corporation (DPC). Ms. D'Alvise has a B.S. in Biochemistry from Michigan Technological University. She has completed post-graduate work at the University of Michigan, Stanford University, and the Wharton Business Schools. Jan has served on the board of numerous private companies and non-profits, and is an Entrepreneur-in-Residence for the von Liebig Institute for Entrepreneurship at the University of California, San Diego.

Linda O'Keefe

Ms. Linda O'Keefe serves as Chief Financial Officer of the Company. Ms. O'Keefe has worked with both public and private biotechnology, diagnostics, medical devices and healthcare services firms, and also in other private equity-financed markets, including business services, education and technology. Prior to joining Acasti, Ms. O'Keefe consulted with various firms after serving as chief financial officer and executive-in-residence for Gryphon Investors, a San Francisco-based private equity firm. At Gryphon Investors, she led fundraising, limited partner relations, risk management and advised portfolio company management teams on growth, financing and back office strategies. In addition, Ms. O'Keefe provided M&A and integration support, established and led audit committees, and supported the expansion of teams and systems to meet the needs of growing companies. Ms. O'Keefe also served as chief financial officer of Delphi Ventures, a healthcare-focused venture capital firm, and Elevate Ventures; as vice president of finance at Genelabs Technologies and Target Therapeutics; and as controller at Collagen Corporation. Ms. O'Keefe is an active Certified Public Accountant and Chartered Global Management Accountant in California and Indiana and was formerly an audit senior with Ernst & Young. She is a member of the American Institute of CPAs, the California and Indiana Societies of CPAs, Association for Corporate Growth, Financial Executives International, and Healthcare Financial Management Association. Ms. O'Keefe holds a Bachelor of Science in Business from the University of California, Berkeley.

Pierre Lemieux

Dr. Pierre Lemieux Ph.D. serves as the Chief Operating Officer of Acasti Pharma Inc., Dr. Pierre Lemieux has been the Chief Operating Officer of the Corporation since April 12, 2010. He holds a post-doctoral degree in Oncology from the Health Science Center, University of Texas (San Antonio), United States, and a PhD in biochemistry from Laval University, Canada, jointly with University of Nottingham, England. Prior to joining the Corporation, Dr. Lemieux was the President, Chief Executive Officer and the chairman of the board as well as being the founder of Technologie Biolactis Inc., a late-stage biotechnology company specialized in the valorization of proteins to better serve the nutraceutical, cosmetic and pharmaceutical industries.

Laurent Harvey

Mr. Laurent Harvey serves as the Vice President, Clinical and Non-Clinical Affairs of the company. Laurent has more than 25 years’ experience in the biopharmaceutical industry, primarily in drug development and clinical research. Before joining Acasti Pharma, he occupied different management positions at Bristol-Myers Squibb, Æterna-Zentaris, Innodia, Bellus Health and KLOX Technologies. During his career, he participated in many national and international clinical programs in various therapeutic fields such as cardiovascular, endocrinology, oncology and neurology. Laurent holds a Bachelor’s degree in pharmacy and M.Sc in hospital pharmacy, both from Université de Montréal.

Jean-Daniel Belanger

Mr. Jean-Daniel Belanger serves as the Corporate Secretary and Director, Corporate Affairs of the company. Mr. Bélanger is Director Corporate Affairs of the Corporation since November 2012 and Corporate Secretary since June 2014. He is in charge of all corporate, governance and securities law matters of the Corporation. He oversees and leads negotiations on corporate and financing matters and is an integral member of the management team, reporting directly to the President and Chief Executive Officer. He holds a law degree from the Université de Montréal (2005) and is a member of the Quebec Bar since 2006. Prior to joining the Corporation, Jean-Daniel was a partner in a Montreal securities boutique-firm, where he practiced in the areas of mergers and acquisitions, corporate finance and securities, and general corporate and commercial law.

Jean-Marie Canan

Katherine Crewe

Ms. Katherine Crewe is Director of the Company. Ms. Crewe has spent 30 years in the medical device and pharmaceutical manufacturing space for companies with sales and distribution networks spanning the globe. During her career, she held several executive positions in various operations and quality management positions, most recently as Managing Director, Canadian operations, at Mallinckrodt Pharmaceuticals. Ms. Crewe is currently Chair of TEC Canada. Ms. Crewe holds a Master of Engineering (Biomedical) from McMaster University and a Bachelor of Science (Chemical Engineering) from Queen's University.

Richard Schottenfeld